Chitinase-3 like-protein-1 may serve as a potential biomarker in RA patients with interstitial lung disease
SENSCIS trial shows nintedanib reduces the decline of lung function in patients with limited cutaneous systemic sclerosis and ILD
Combined therapy of tofacitinib plus iguratimod improves rheumatoid arthritis-usual interstitial pneumonia
